Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC
FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC